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ABSTRACT 
 
The High mobility group A (HMGA) non-histone chromosomal proteins play 
key roles in chromatin architecture and orchestrate the assembly of 
nucleoprotein complexes involved in gene transcription, replication, and 
chromatin structure. HMGA overexpression and gene rearrangement are 
frequent events in human cancer. Their importance in cancer progression and 
their role in apoptosis has been defined by a new physical and functional 
interaction between HMGA1 and p53 proteins. HMGA1 inhibits p53-mediated 
apoptosis modulating the transcription of p53 target genes as Mdm2, p21Waf1, 
Bax, Bcl-2 and promoting Hipk2 relocalization from the nucleus to the 
cytoplasm. Even though HMGA1 proteins have been identified as nuclear 
proteins, abundant HMGA1 expression has been frequently detected in the 
cytoplasm of cancer cells but it has been often considered as an artefact likely do 
a very abundant HMGA1 expression, and no deep investigation has been 
undertaken to clearly demonstrate the presence of these proteins in the 
cytoplasm, and to unveil the functional role of this localization. Preliminary 
studies obtained by a screening of an Antibody ArrayTM strongly suggest 
possible cytoplasmic interactors of HMGA1 proteins in tumoral cell lines.  
My thesis project is focalized on the interaction between HMGA1 and anti-
apoptotic factor Bcl-2. I have identified and characterized a new subcellular 
localization of HMGA1 proteins by analysis of total, nuclear and cytoplasmic 
cell lysates from several normal, and tumor-derived cell lines. Then, I confirmed 
the interaction HMGA1-Bcl-2 in cytoplasm in vivo and in vitro. Moreover, since 
p53 interacts with Bcl-2 blocking its anti-apoptotic function, I identified a new 
mechanism that allows HMGA1 proteins to inhibit the p53-mediated intrinsic-
apoptotic pathway. Indeed, HMGA1 localizes at mitochondria and displaces it 
from the binding to Bcl-2 enhancing its anti-apoptotic function.  
Finally, I reported the correlation between the HMGA1 cytoplasmic localization 
and a more aggressive phenotype in thyroid, breast and colon cancer. 
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1. BACKGROUND 
 
1.1 HMGA protein family 
Cell proliferation and differentiation are highly coordinated processes during 
development and require the precise regulation of gene expression. One process 
that facilitates the orchestration of these changes in gene expression patterns is 
remodelling of chromatin structure, which in turn modulates the interaction of 
transcription regulatory proteins with DNA. These changes in chromatine 
structures are effected by so-called “architectural transcription factors” (Muller 
et al. 2001). 
The high mobility group (HMG) proteins are abundant heterogeneous, non-
histone components of chromatine that act as such architectural factors 
contributing to transcriptional regulation. The HMGA proteins, including 
HMGA1 (isoforms HMGA1a, HMGA1b, HMGA1c) and HMGA2, are the key 
of assembly of multiprotein complexes of transcriptional factors and co-factors, 
which constitute the so called “transcriptome” or “enhanceosome” of several 
genes. The HMGA proteins have a similar structure and are well conserved 
during evolution. Each protein contains three DNA binding domains containing 
short basic repeats, the so-called “AT-hooks”, with which they bind AT-rich 
sequences in the minor groove of DNA, and an acidic carboxy-terminal tail that 
is believed to be important for protein-protein interaction and for recruitment of 
specific proteins to enhanceosome (Reeves et al. 2001). 
The human HMGA1 gene, located at the chromosome band 6p21, spans 10 kb 
and consists of 8 exons, among which only exons from 5 to 8 are transcribed in 
mRNA and codes for the HMGA1 proteins that have a molecular weight of 19-
20 kDa (Friedmann et al. 1993). The HMGA1a and HMGA1b proteins are 
identical in sequence except for an internal deletion of 11 amino acids in the 
latter, and are also the most abundant of these spliced variants in mammalian 
cells (Figure 1.1) (Johnson et al. 1989; Friedmann et al. 1993). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Schematic representation of HMGA1a and HMGA1b proteins.
Each protein contains three
they bind DNA, and an acidic carboxy
 
 
A new HMGA1 isoform
nucleotides deletion at RNA level in comparison to the HMGA1 sequence. 
This deletion results in a frameshift so that the two proteins are identical in their 
first 65 amino acids and differ thereafter. 
amino acids with molecular weight of 26
Little is known about thi
transcript present in normal human and mouse testis (Chieffi 
Then, the human HMGA2 
more than 140 kb and consist
protein (Figure 1.2). Alternati
detected in leiomyoma tumors (Hauke 
 
 basic domain, named AT hook (green box), with which 
-terminal region (red box). 
, HMGA1c, has been isolated and consists of a 67 
HMGA1c encodes a protein of 172 
-27 kDa (Nagpal et al. 1999).
s isoform, however, it appears to be the only 
et al.
gene, located at chromosom band 12q13
s of 5 exons, all of them coding for 
ve spliced mRNAs from this gene have also 
et al. 2001; Kurose et al. 2001).
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Figure 1.2. Schematic representation of HMGA2 protein. HMGA2 protein contains 
three basic domain, named AT hook (green box), with which they bind DNA, and an 
acidic carboxy-terminal region (red box). 
 
Both HMGA genes are widely expressed during embryogenesis, whereas their 
expression is absent or low in adult tissues (Zhou et al. 1995, Chiappetta et al. 
1996). In particular, expression of HMGA2 has not been detected in any of the 
several adult mouse and human tissues tested (Rogalla et al. 1996).  
Low expression has been observed in CD34-positive haematopoietic stem cells 
(Rommel et al. 1997), in mouse preadipocytic proliferating cells (Anand and 
Chada 2000) and in meiotic and post-meiotic cells secondary spermatocytes and 
spermatidis (Chieffi et al. 2002, Di Agostino et al. 2004). Conversely, HMGA1 
is ubiquitary expressed albeit at low levels, in adult murine and human tissues 
(Chiappetta et al. 1996). 
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1.2 Multiple functions of HMGA proteins 
 
Many reports illustrate how the HMGA proteins participate in processes such as 
the regulation of gene expression, virus integration and expression, 
embryogenesis, differentiation and neoplastic transformation. 
In normal cells, the expression of HMGA proteins is restricted to 
embryogenesis, it decreases with organogenesis and in normal adult cells is very 
low or almost absent. At later stages, the expression pattern becomes more 
restricted; in particular, HMGA1 expression is confined to specific body organs 
of ectodermal, mesodermal and endodermal origin, while HMGA2 expression is 
restricted to those of mesenchimal origin. 
After embryogenesis, the HMGA genes are re-expressed at high levels in 
transformed cells and in tumors. This elevated expression, detected in a variety 
of tumors having different origins (Giancotti et al. 1989, Fedele et al. 1996), 
suggested that these proteins could be used as diagnostic markers of neoplastic 
transformation/progression. Indeed, it has been well established that many 
human neoplasias, including thyroid, prostatic, cervical, colorectal, pancreatic 
and ovarian carcinoma, show a strong increase of both HMGA1a and HMGA1b 
proteins (Chiappetta et al. 1998; Bandiera et al.1998; Abe et al. 2000; Kim et al. 
1995; Chiappetta et al. 2001; Abe et al. 2002; Abe et al. 2003; Masciullo et al. 
2003; Fusco and Fedele 2007). The first evidence of a direct role played by these 
factors in tumorigenesis came from transfection in normal rat thyroid cells of an 
antisense construct for HMGA2 that prevented retrovirally induced neoplastic 
transformation (Berlingieri et al. 1995). The increased expression of HMGA 
proteins was later shown to promote tumor progression in different cell lines. 
In addition of overexpression, HMGA proteins was later shown to promote 
tumour progression in different cell lines.  
In addition of overexpression in malignant tumors, HMGA de-regulation, as a 
result of specific chromosomal rearrangements, has also been reported in a 
variety of common benign tumours. Structure alterations for both HMGA genes 
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have been reported, but rearrangements of HMGA2 gene at 12q15 are particulary 
frequent especially in lipomas and leiomyomas, making this gene probably the 
most commonly rearranged one in human neoplasia. 
 
 
 1.3 Mechanisms of action of HMGA proteins 
 
The HMGA proteins have roles in assembling or modulating macromolecular 
complexes that are involved in various biological processes: HMGA proteins 
directly bind to the DNA, modifying its conformation and consequently 
facilitating the binding of a group of transcriptional factors (TF). They interact 
with both DNA and TFs to generate a multiprotein stereospecific complex bound 
to DNA (Fig. 1.3 a). 
HMGA proteins have been shown to participate in this way in the regulation of 
many genes, the best studied being the interferon (IFN)-β gene (Thanos D, 
Maniatis T, 1992). 
The activation of IFN-β expression is due to a multifactor complex that 
assembles in the nucleosome-free enhancer region of the gene, including the 
factors NFkB, interferon regulatory factor, activating transcriptional factor 
(ATF2)/JUN and the HMGA1a protein. 
The HMGA proteins can also influence gene transcription through protein-
protein interactions with transcription factors (Figure 1.3 b) by modifying its 
conformation and enhancing the affinity of its binding to DNA.  
The enhancement of transcriptional activity of the TF serum-response factor by 
HMGA1a is an example of this mechanisms (Chin et al. 1998).  
Finally, the HMGA proteins have the ability to alter chromatin structure (Figure 
1.3 c). Indeed, they have been shown to be important elements that are 
associated with matrix and scaffold-associated regions. They are specific 
segments of genomic DNA that have a high affinity for the nuclear matrix and 
that are enriched in AT sequences. These sequences anchor chromatin to the 
nuclear scaffold and organize topologically independent DNA domains which 
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have functional roles both in DNA replication and transcription (Galande S.et al. 
2002). The binding of HMGA proteins to these regions de-represses 
transcription by displacement of histone H1 by DNA. 
 
 
 
      
 
 
 
 
 
Figure 1.3 a) HMGA proteins bind Dna; b) HMGA are involved in protein-protein 
interaction; c) HMGA proteins alter the chromatine structure. 
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1.4 Regulation of gene expression by HMGA proteins 
The regulation of gene transcription in eukaryotic cells depends by chromatine 
structure. HMGA proteins do not have transcriptional activity per se; however, 
by interacting with the transcription machinery they alter the structure and 
thereby regulate, negatively or positively, the transcriptional activity of several 
genes (Thanos,D. et al. 1992; Thanos D. et al. 1993);(Table 1.1). 
HMGA proteins might participate in the regulation of gene transcription, 
influencing chromatin structure, by two mechanisms: one model suggests that 
HMGA proteins act to influence the structure of large regions or domains of 
chromatin, whereas a second model assumed a restricted or localized effect on 
chromatin and nucleosome structure. The promoter regions of many of these 
regulated genes contain multiple AT-rich sequence that represent a gene-specific 
‘bar code’ that is read by the AT-hooks of the HMGA proteins during the 
process of transcriptional activation (Reeves and Beckerbauer 2001). 
Transcriptional activation of these types of promoters often involves the 
formation of an “enhanceosome”, a stereo-specific, multi-protein complex that 
includes HMGA proteins and other transcription factors making specific protein-
DNA and protein-protein contacts.  
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Table 1.1 Genes regulated by HMGA proteins 
 
POSITIVE REGULATION 
 
Vascular endothelial tissue related 
 
E-selectin (Lewis et al. 1994) 
IGFBP-1(Allander et al.1997) 
COX-2 (Ji et al. 1998) 
 
SM22α (Chin et al. 1998) 
INOS(Perrella et al.1999) 
CD44 (Foster et al. 2000) 
 
 
Immune system related 
 
IL-2 (Reeves et al. 1987) 
TNF-β (Fashena et al. 1992) 
INF-β (Thanos et al. 1992) 
 IL-2Rα (John et al. 1995)   HLA-
II (Abdulkadir et al. 1995) 
 
MSGA/GROα (Wood et al. 1995)  
GM-CSF (Himes et al. 1996) 
 
IgG heavy chain (Sobasjima et al. 1997) 
c-fos (Chin et al. 1998) 
 
CXCL1 (Nirodi et al. 2001) 
 
Viral genes 
 
JV virus early and late genes (Leger et al. 1995) 
HSV-1 IE3 (French et al. 1996) 
HIV-1 LTR (Farnet et al. 1997) 
HSV-1 EBNA1 (Sears et al. 2003) 
BV EBNA1 (Sears et al. 2003) 
 
 
 
 
 
 
Cell cycle related 
 
Cyclin A (Tessari et al. 2003)  
Cyclin E (Fedele et al. 2006) 
 CDC2 (Fedele et al. 2006) 
 
CDC6 (Fedele et al. 2006)  
CDC25A (Fedele et al. 2006) 
 
 
Others 
 
Tyrosinase (Sato et al. 1994) 
 PKCγ (Xiao et al. 1996) 
 Rhodopsin (Chau et al. 2000) 
 
Neurogranin IRC3 (Xiao et al. 2000)  
Leptin (Melillo et al. 2001) 
 
Mdm2 (Pierantoni et al. 2006) 
 
 
NEGATIVE REGULATION 
 
GP 91-phox (Skalnik et al. 1992) 
 IL-4 (Chuvpilo et al. 1993) 
 
IgE (Kim et al. 1995) 
TCRα (Bagga et al. 1997) 
β-globin (Chase et al. 1999) 
α-EnaC (Zentner et al. 2001)  
BRCA1 (Baldassarre et al. 2003) 
 RAG2 (Battista et al. 2005) 
 
Bax (Pierantoni et al. 2006) 
 p21 (Pierantoni et al. 2006) 
 Hand1 (Martinez Hoyos et al. 2008) 
 
 
 
1.5 Role of HMGA proteins in development 
 
The high expression of HMGA proteins during embryogenesis suggests that they 
have an important role in development and are involved in the control of cell 
growth and differentiation. Infact, it has been demonstrate that HMGA proteins 
induce premature gene transcription in early mouse embryos (Beaujean et 
al.2000) and from our findings that HMGA proteins are critical players in 
controlling the growth and differentiation of pre-adipocytes 3T3-L1 cells 
(Melillo et al. 2001). Then, HMGA genes and their proteins are rapidly induced 
in quiescent normal cells following exposure to factors that stimulate metabolic 
 13 
 
activation and growth providing additional evidence (Friedmann et al. 1993; 
Johnson et al. 1990; Ogram and Reeves 1995; Holth et al. 1997).  
Also the phenotypic characterization of knockout mice for each of the HMGA 
genes confirms crucial roles for these proteins in different aspects of 
development. Indeed, cardiac hypertrophy and type 2 diabetes were observed in 
hmga1-null and heterozygous mice (Foti et al. 2005; Fedele et al. 2006) 
suggesting that quantitatively appropriate expression of the HMGA1 proteins are 
required for cardiomyocytic cell growth and function of the insulin pathway. 
Instead, hmga2-null and heterozygous mice showed a pygmy phenotype with a 
decreased body size of 20% in heterozygous and 60% in homozygous mice, as 
well as a drastic reduction of the fat tissue (Zhou et al. 1995), suggesting an 
important role of the Hmga2 gene in the control of body growth and adipocyte 
proliferation and differentiation. Therefore, although HMGA1 and HMGA2 may 
have overlapping functions, they seem to have different roles in development. 
 
 
1.6  Role of HMGA proteins in cancer 
 
In contrast to normal tissues, high levels of HMGA1 and HMGA2 are a common 
feature of human benign and malignant tumors. The correlation between the 
levels of HMGA proteins and the malignant phenotype made it important to 
determinate their role in the process of cell transformation and, in particular, to 
investigate whether their increase is a phenomenon associated with cell 
transformation or whether it has a causative relationship with the malignant 
phenotype. 
Benign tumors of mesenchymal origin (lipomas, leiomyomas, fibroadenomas, 
pulmonary hamartomas and endometrial polyps) often contain chromosomal 
rearrangements involving HMGA2 gene. These rearrangements result in the 
formation of new hybrid genes that code for chimeric proteins in which the AT-
hooks of HMGA2 are fused to ectopic peptidic sequences (Hess 1998), with loss 
of the C-terminus and of the 3’UTR of the gene.  
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It is probably that the truncation of HMGA2 gene and loss of its 3’UTR rather 
than the formation of a new chimeric gene is crucial for cell trasformation 
(Kazmierczak et al.1995, Kools and Van de Ven et al. 1996).  
Rearrangements and overexpression of the HMGA2 gene have also been 
described in non-mesenchymal benign human tumors, such as pituitary 
adenomas (Finelli et al. 2002, Pierantoni et al. 2005).  
Consistently, transgenic mice overexpressing HMGA1 or HMGA2 develop 
pituitary adenomas, demostrating the casual role of HMGA proteins in the 
transformation of pituitary gland (Fedele et al. 2002, Fedele et a.l 2005). 
In addiction, the antisense-mediated inhibition of HMGA protein synthesis 
suppresses their malignant phenotype (Berlingieri et al. 1995; Berlingieri et al. 
2002), induces apoptotic death in thyroid carcinoma cells but not in normal 
thyroid cells (Scala et al. 2000), and inhibits proliferation of some breast 
carcinoma cell lines (Reeves et al. 2001). 
Overexpression of HMGA proteins is a costant feature of several human 
malignant neoplasias, including thyroid, prostate, uterus, breast, lung, uterine 
cervix, colonrectum, ovary and pancreas carcinomas (Fedele et al. 2001). 
Moreover, HMGA protein expression is associated with a highly malignant 
phenotype (Tallini and Dal Cin 1999) and is a poor prognostic index as their 
overexpression often correlates with the presence of metastasis and with reduced 
survival (Fusco and Fedele 2007); (Table 1.2). 
 
 
 
Table 1.2 Cancers associated with aberrant expression of HMGA proteins 
 
Overexpression of full-length proteins 
 
Lewis lung carcinoma (Giancotti et al. 1989) 
 
Prostrate (Tamimi et al. 1993) 
 
Thyroid neoplasias (Chiappetta et al. 1995) 
 
Colorectal (Fedele et al.1996) 
 
Squamous carcinoma of uterine cervix (Bandiera et al. 1998) 
 
Non-small cell lung carcinoma (Rogalla et al. 1998) 
 
Neuroblastomas (Giannini et al. 1999) 
 
Burkitt's lymphoma (Wood et al. 2000) 
 
Lipomas (Fedele et al. 2001) 
 
Pancreatic duct cell carcinoma (Abe et al. 2002) 
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Breast (Baldassarre et al. 2003) 
 
Lymphoblastic leukemia (Pierantoni et al. 2003) 
 
Ovarian carcinoma (Masciullo et al. 2003) 
 
Testicular germ cell tumours (Esposito et al. 2008) 
 
Chromosomal translocations/AT hook rearrangements 
 
Myeloid leukemias (Elton et al. 1986) 
 
Thyroid neoplasias (Chiappetta et al. 1995) 
 
Pulmonary chondroid hamartomas (Kazmierczak et al. 1996) 
 
Uterine leiomyomas (Hennig et al. 1996) 
 
Endometrial polyps (Hennig et al. 1996) 
 
Breast hamartoma (Dal Cin et al. 1997) 
 
Lipomas (Fedele et al. 2001) 
 
 
 
The mechanisms that lead to transformation are based on the ability of the 
HMGA proteins to downregulate or upregulate the expression of genes that have 
a crucial role in the control of cell proliferation and invasion. Recently, it has 
been reported that HMGA2 induces pituitary adenomas in Hmga2-transgenic 
mice by binding to pRB and enhancing E2F1 activity (Fedele et al. 2006).  
In fact, HMGA2 is able to displace histone deacetylase 1 from the pRB-E2F1 
complex, resulting in enhanced acetylation of both E2F1 and DNA-associated 
histones, thereby promoting E2F1 activation. The crucial role of HMGA2-
mediated E2F1 activation for pituitary tumorigenesis was confirmed by crossing 
Hmga2-overexpressing mice with E2f1 knock-out mice, which suppressed 
tumorigenesis (Fedele et al. 2006).  
It is reasonable to argue that increased E2F1 activity might also have an 
important role in other neoplasias, or aberrant cell-proliferation conditions, 
where HMGA2 is overexpressed. The pygmy phenotype of the Hmga2-null mice 
(Zhou et al. 1995) may result from decreased E2F1 activity that would 
eventually lead to decreased embryonic cell proliferation.  
Another mechanism by which the HMGA proteins might have a role in cancer 
progression is through their interaction with p53. It has been found that HMGA1 
binds p53 protein in vitro and in vivo, and interferes with the p53-mediated 
transcription of p53 effectors Bcl2-associated X protein (Bax) and cyclin-
  
dependent kinase inhibitor 1A (p21Waf1/Cip1), as well as cooperating with
to activate transcription of the 
of p53-dependent apoptosis in c
endogenous HMGA1 after activation by UV
(Figure 1.4). 
 
                   
 
 
 
Figure 1.4 HMGA1 regulates Bax transcription
p53 up-regulate the transcription of pro
the activity of p53 on Bax promoter.
promoter, it acts in the regulation of these promoters only cooperating with p53 protein.
 
 
Moreover, HMGA1 can also interfere with the apoptotic function of p53 by 
another mechanism that increases the interaction with the proapoptotic p53 
activator homeodomain
kinase (Pierantoni et al.
HIPK2 relocalization in the cytoplasm and inhibition of p53 apoptotic function, 
whereas HIPK2 overexpression re
sensitivity to apoptosis (Pierantoni 
Consistent with this process, strong correlations
overexpression, HIPK2 cytoplasmic localization and a low spontaneous 
p53 inhibitor MDM2. This results
ells expressing p53 and exogenous or
 light (Pierantoni 
. 
-apoptotic factor Bax, the co-expression of HMGA1 reduce 
 HMGA1 expression alone did not affect the ac
-interacting protein kinase 2 (HIPK2), a serin threonine 
 2007). HMGA1 overexpression promotes endogenous 
-establishes HIPK2 nuclear localization and 
et al. 2007), (Figure 1.5).  
 among HMGA1 
16 
 p53 
 in a reduction 
 
et al. 2006), 
 
tivity of any 
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apoptosis index (comparable to that observed in tumours with mutated p53) were 
observed in human breast carcinomas expressing wild-type p53 (Pierantoni et al. 
2007).  
Therefore, HMGA1 inhibits p53-dependent apoptosis by modulating both 
transcription of p53 target genes and cytoplasmic relocalization of HIPK2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Schematic representation of p53 inhibition by high mobility group A (HMGA)1. 
In response to DNA damage, p53 induces either cell-cycle arrest or apoptosis. p53 
phosphorylation at S46 by homeodomain-interacting protein kinase 2 (HIPK2) is one determinant 
of the outcome because it occurs only after severe, non repairable DNA damage that irreversibly 
drives cells to apoptosis. HMGA1 overexpression inhibits the p53 apoptotic function by two main 
mechanisms: it promotes HIPK2 relocalization in the cytoplasm, and it directly binds to p53 and 
interferes with the p53-mediated transcription of apoptotic and cell-cycle arrest effectors, while it 
cooperates with p53 in the transcriptional activation of the p53 inhibitor MDM2. 
 
We have identified also another mechanism by which HMGA1 overexpression 
contributes to escape from apoptosis leading to neoplastic transformation based 
on Blc-2 induction. In fact, HMGA1 overexpression promotes the reduction of 
Brn-3a binding to the Bcl-2 promoter, thereby blocking the Brn-3a corepressor 
function on Bcl-2 expression following p53 activation. In particular HMGA1 
overexpression promote Hipk2 relocalization in the cytoplasm and inhibition of 
p53 transcriptional repression exerted on the Bcl-2 promoter, while HIPK2 over-
expression reestablished HIPK2 nuclear localization and sensivity to apoptosis 
(Figure 1.6A).  
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Moreover, HIPK2 is not only able to phosphorylate and activate p53, but also to 
enhance Brn3a DNA binding that, when p53 is active, works as a corepressor of 
Bcl-2 transcription. My results demonstrate that HMGA1 overexpression 
promotes not only HIPK2 delocalization from nucleus to the cytoplasm, but also 
the reduction of Brn-3a binding to the Bcl-2 promoter removing Brn-3a from its 
role of corepressor following p53 overexpression (Figure 1.6 B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Induction of Bcl-2 expression By HMGA proteins 
A) Hipk2 phosphorylates p53 that represses Bcl-2 promoter.HMGA1 overexpression  promove 
Hipk2 relocalization in the cytoplasm and inhibits the repression exerted by p53 on Bcl-2 
promoter. B) Brn3a acts as corepressor of Bcl-2 transcription. The overexpression of HMGA1 
promotes Hipk2 delocalization from nucleus to the cytoplasm and the reduction of Brn3a binding 
on Bcl-2 promoter. 
 
 
These mechanisms described might have important implications in 
tumorigenicity as well as in the development of the tumor resistance to 
antineoplastic treatments. 
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1.7 Interactors of HMGA proteins 
 
Another important charcteristic of HMGA proteins is the capability to interact 
directly with many transcriptional factors. As reported in Table 1.3, 21 different 
transcription factors have been identified by coimmunoprecipitation assay and 
pull down assay.  
These interactors have two points in common: the sites of interaction include 
part, or all, of more AT-hook peptide motifs plus some flaking regions and these 
sites include amino acid residues that are known to be extensively modified in 
vivo by post-translation modifications like phosphorylation, acetylation or 
methylation. In particular, post-translation modifications are important because 
alter the interaction of the HMGA proteins with DNA and chromatin substrates. 
Labile biochemical modifications are, therefore, likely to modulate other specific 
HMGA-protein interactions in vivo and influence, for example, enhanceosome 
formation and gene transcriptional activity and/or a wide variety of other 
biological processes. 
 
 
 
Table 1.3 Transcription factors that physically interact with HMGA proteins 
 
 
NF-kB p50 homodimer (Lewis et al. 1994)  
NF-kB p65 homodimer (Lewis et al. 1994) 
 NF-kB p50/p65 heterodimer (Lewis et al. 
1994)  
AP-1 (Ogram et al. 1995) 
 
ATF-2/c-jun heterodimer (Falvo et al. 1995) 
PU.1 (Nagulapalli et al. 1995) 
 
Tst-1/Oct-6 (Leger et al. 1995) 
c-jun (Falvo et al. 1995)  
C/EBPβ (Νagulapalli et al. 1995) 
Elf-1 (John et al. 1995) 
 
NF-AT (Klein et al. 1996) 
 
 
IRF-1 (Schaefer et al. 1997)  
NF-Y (Louis et al. 1997)  
Oct-1 (Abdulkadir et al. 1998) 
 
Oct-2A (Abdulkadir et al. 1998)  
SRF (Chin et al. 1998) 
 
RNF4 (Fedele et al. 2000) 
PATZ (Fedele et al. 2000) 
PIAS3 (Zentner et al. 2001)  
p53 (Pierantoni et al. 2006) 
Rb (Fedele et al. 2006) 
 
 20 
 
1.8 The tumor suppressor p53 
Human p53 is a nuclear phosphoprotein of MW 53 kDa, encoded by a 20-Kb 
gene containing 11 exons and 10 introns (Lamb and Crawford 1986) which is 
located on the small arm of chromosome 17 (Isobe et al. 1986). This gene 
belongs to a highly conserved gene family containing at least two other 
members, p63 and p73. Wild-type p53 protein contains 393 amino acids and is 
composed of several structural and functional domains (Figure1.7): a N-terminus 
containing an amino-terminal domain (residues 1-42) and a proline-rich region 
with multiple copies of the PXXP sequence (residues 61-94, where X is any 
amino acid), a central core domain (residues 102-292), and a C-terminal region 
(residues 301-393) containing an oligomerization domain (residues 324-355), a 
strongly basic carboxyl-terminal regulatory domain (residues 363-393), a 
nuclear localization signal sequence and three nuclear export signal sequences 
(Vousden and Lu 2002). 
 
 
 
 
 
 
 
 
 
Figure 1.7. Schematic representation of the p53 structure. p53 contains 393 amino 
acids, consisting of three functional domains, i.e. an N-terminal activation domain, 
DNA binding domain and  C-terminal tetramerization domain. The N-terminal domain 
includes transactivation subdomain and a PXXP region that is a proline-rich fragment. 
The central DNA binding domain is required for sequence-specific DNA binding and 
amino acid residues within this domain are frequently mutated in human cancer cells 
and tumor tissues. The Arg175, Gly245, Arg248, Arg249, Arg273, and Arg282 are 
reported to be mutation hot spots in various human cancers. The C-terminal region is 
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considered to perform a regulatory function. Residues on this basic C-terminal domain 
undergo post-translational modifications including phosphorylation and acetylation. 
Numbers indicate residue number. NLS, nuclear localization signal sequence; NES, 
nuclear export signal sequence. 
 
The amino-terminal domain is required for transactivation activity and interacts 
with various transcription factors including acetyltransferases and MDM2 
(murine double minute 2, which in humans is identified as Hdm2) (Fields and 
Jang 1990; Lin et al. 1994). The proline-rich region plays a role in p53 stability 
regulated by MDM2, where in p53 becomes more susceptible to degradation by 
MDM2 if this region is deleted (Sakamuro et al. 1997). The central core of this 
protein is made up, primarily, of the DNA-binding domain required for 
sequence-specific DNA binding (the consensus sequence contains two copies of 
the 10-bp motif 5’-PuPuPuC(A/T)-(T/A)GPyPyPy-3’, separated by 0-13 bp) 
(Kern et al. 1991). The basic C-terminus of p53 also functions as a negative 
regulatory domain (Vousden and Lu 2002), and has been implicated in induction 
of cell death (Chen et al. 1996). According to the allosteric model, in which C-
terminal tail of p53 was considered as a negative regulator and may regulate the 
ability of its core DNA binding domain to lock the DNA binding domain as a 
latent conformation. If the interaction between the C-terminus and the core DNA 
binding domain is disrupted by post-translational modification (such as 
phosphorylation and acetylation), the DNA binding domain will become active, 
thus induce an enhanced transcriptional activity. The central region of p53 is its 
most highly conserved region, not only when p53 is compared with its 
homologues from Drosophila and Caenorhabditis elegans, but also as compared 
with its mammalian family members, p63 and p73 (Kaelin 1999).  
Structural studies of p53 have revealed that the majority of p53 mutations found 
in cancers are missense mutations that are mostly located in the central DNA-
binding domain, and more than 80% of p53 mutation studies have focused on 
residues between 126–306 (Cho et al. 1994). 
 Acquired mutations (more than 18,000 mutations have been identified) in the 
TP53 gene are found in all major types of human cancers. Approximately half of 
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all human tumors have a mutation or loss in the p53 gene leading to inactivation 
of its function (Soussi and Beroud 2001; Bode and Dong 2004). For example, 
p53 mutation frequency is 70% in lung cancer, 60% in cancers of colon, head 
and neck, ovary, and bladder, and 45% in stomach cancer. In many of the others, 
approximately 50% human tumors in which p53 is not functionally inactive, p53 
function is impaired owing to mutations in proteins operating either upstream or 
downstream of p53 targets, such as MDM2 or the E6 protein of HPV, or deletion 
of key p53 co-activators such as the ARF gene (Hollstein et al. 1991; Sherr 
1998; Vogelstein et al. 2000). 
 
1.9 p53 functions 
As a tumor suppressor, p53 is essential for preventing inappropriate cell 
proliferation and maintaining genome integrity following genotoxic stress 
(Vogelstein et al. 2000; Vousden and Lu 2002). Following various intracellular 
and extracellular stimuli such as DNA damage (by means including ionizing 
radiation, UV radiation, application of cytotoxic drugs or chemotherapeutic 
agents, and infectious virus), heat shock, hypoxia, and oncogene overexpression, 
wt p53 is activated and emerges as a pivotal regulatory protein which triggers 
different biological responses, both at the level of a single cell as well as in the 
whole organism (Levine 1997; Vogelstain et al. 2000; Vousden and Lu 2002). 
p53 activation involves an increase in overall p53 protein level and qualitative 
changes in the protein through extensive post-translational modifications, thus 
resulting in activation of p53-targeted genes (Fritsche et al. 1993).  
The induction of the transcription dependent cell death program requires p53 
phosphorylation at Ser 46, which is necessary for the apoptosis (Oda et al. 2000) 
and determines whether apoptosis is attenuated or amplified.  
Phosphorylation of p53 at Ser 46 critically depends on the serine/threonine 
kinase HIPK2 (D’Orazi et al. 2002) which enhances the transcriptional activity 
of p53 to promote apoptosis (D’Orazi et al. 2002; Hofmann et al. 2002). Genes 
activated by wt p53 are functionally different and constitute downstream 
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effectors of signaling pathways that elicit different responses such as cell-cycle 
checkpoints, cell survival, apoptosis, and senescence (Hofseth et al. 2004).  
Many of the multiple functions of p53 including the primary role of p53 in 
tumor suppression can be attributed to its ability to act as a sequence-specific 
transcription factor which regulates expression of different cellular genes to 
modulate various cellular processes (Farmer et al. 1992), although protein-
protein interactions may also play a role. 
In response to various types of stress, p53 is accumulated in the nucleus, binds to 
specific sites in the regulatory regions of p53-responsive genes, and then 
strongly promotes the transcription of such genes (Kern et al. 1991). 
The p53 downstream targets are differentially activated depending on the cell 
type, extent of the damage which has influenced p53 activation, and various 
others as yet unidentified parameters (Oren 2003). Many approaches have been 
employed to identify the targets of p53 in various experimental systems (Yang et 
al. 2004). As a result of these efforts, hundreds of physiologically p53 
responsive genes have been reported. These genes are principally involved in 
cell cycle arrest and DNA repair, as well as apoptosis and senescence-related 
genes, such as genes for p21Waf1/Cip1, Gadd45 (growth arrest and DNA-damage 
inducible protein 45) and genes of the Bcl-2 family (Vousden and Lu 2002; 
Fridman and Lowe 2003). Genes which may be repressed by p53 include Bcl-2, 
Bcl-x, Cyclin B1, MAP4 and Survivin, some of which are negative regulators of 
apoptosis (Vousden and Lu 2002; Hofman et al. 2002).  
Intriguingly, using ovarian cancer cells infected with p53-expressing adenovirus 
indicated that approximately 80% of the putative p53-responsive genes are, in 
fact, repressed by p53 (Mirza et al. 2003). The functions of p53 target genes are 
diverse, corresponding to p53’s activity as a multifunctional protein.  
The products of these gene may induce apoptosis through either an extrinsic or 
an intrinsic pathway, namely the death receptor pathway and the mitochondrial 
pathway respectively (Figure 1.8). 
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Figure 1.8. p53-associated genes and pathways involved in apoptotic cell death. 
p53 induces apoptosis mainly via two pathways: extrinsic and intrinsic pathways. The p53-
associated extrinsic pathway is mainly executed by activating caspase-8 to induce apoptosis, 
whereas the p53-associated intrinsic pathway is almost executed by influencing mitochondrial 
proteins, by which activate caspase-9 to induce apoptosis. In addition, p53 may directly activate 
Apaf-1 to induce apoptosis. 
 
 
Recently, an emerging area of research unravels additional activities of p53 in 
cytoplasm, where it triggers apoptosis and inhibits autophagy (Douglas et al. 
2009). Activation of cytosolic p53 can directly induce mitochondrial outer 
membrane  permeabilization (MOMP) by forming inhibitory complexes with the 
protective Bcl-XL and Bcl-2 proteins, resulting in cytocrome c release.  
MOMP is usually inhibited by anti-apoptotic multidomain proteins of Bcl-2 
family (such as Bcl-2, Bcl-XL and Mcl-1), and is conditional on pro-apoptotic 
multidomain proteins from the same family (in particular Bax and Bak) that can 
homo-oligomerize within the outer mitochondrial membrane to form MOMP-
mediating supramolecular structures. A set of distinct pro-apoptotic “BH3-only” 
proteins can directly interact with Bax or Bak to trigger their homo-
oligomerization and hence MOMP and/or neutralize one or more anti-apoptotic 
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multidomain proteins. p53 has been suggested to act like a BH3-only protein, 
either as a direct activator of Bax and/or Bak or as a de-repressor (Motohiro et 
al. 2003). The pro-apoptotic effects of cytoplasmic p53 are not dependent on 
transcription (Figure 1.9). However the control of transcription by nuclear p53 
decisively contributes to the function of cytoplasmic p53. The ability of p53 to 
induce apoptosis appears to be well correlated with its ability to suppress 
malignant transformation. Loss of p53-dependent apoptosis accelerates mouse 
brain tumorigenesis (Symonds et al.1994). These results reveal that regulation of 
apoptosis is an important and evolutionarily conserved tumor suppressor 
function of p53. 
    
       
 
      
Figure 1.9 Classification of p53 activities. On the left side, some genes that are transactivated 
by p53 are exemplified, together with a few of the functional consequences of p53 activation. On 
the right side, transactivation –indipendent effects of p53 are listed. These can be divided into 
nuclear and extra-nuclear (cytoplasmic) p53 activies. 
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1.10 Bcl-2 and apoptosis 
Bcl-2 family proteins serve as critical regulators of pathways involved in 
apoptosis, acting to either inhibit or promote cell death. Altered expression of 
these proteins occurs commonly in human cancers, contributing to neoplastic 
cell expansion by suppressing programmed cells death and extending tumor cell 
life span. Moreover, because chemotherapeutic drugs typically exert their 
cytotoxic actions by inducing apoptosis, the ultimate efficacy of most anticancer 
drugs can be heavily influenced by the relative levels and state of activation of 
members of the Bcl-2 family (John C Reed Oncogene 1998).  
The apoptosis-suppressing Bcl-2 gene was discovered as a proto-oncogene found 
at the breakpoints of t(14;18) chromosomal traslocations in low-grade B-cell 
lymphomas. Initial gene transfection studies of Bcl-2 demonstrated that over-
production of the protein significantly prolongs cell survival in the face of 
classical apoptotic stimuli, including lymphokine deprivation from factor-
dependent hematopoietic cells, glucocorticoid treatment of thymocytes and 
lymphoid leukemia cells, ϒ-irradiation of thymocytes, and NGF-deprivation 
from fetal sympathetic neurons (reviewed in Reed, 1994). Conversely, antisense- 
mediated suppression of Bcl-2 expression was demonstrated to induce or 
accelerate cell death (Reed et al., 1990). It was thus that Bcl-2 emerged as the 
first example of an intracellular apoptosis-suppressor and the first identified 
proto-oncogene which contributed to neoplasia through effects on cell life span 
regulation rather than cell division. 
 Bcl-2 is a multifunctional protein. Three general functions for Bcl-2 and some 
of its anti-apoptotic homologous such as Bcl-XL have been identified: a) 
dimerization with other Bcl-2 family proteins; b) binding to non-homologous 
proteins; and (c) formation of ion-channels/pores (Reed 1997; Schendel et al. 
1998; Vaux and Strasser, 1996; Zamzami et al., 1998).  
The Bcl-2 family proteins are composed of three classes: anti-apoptotic proteins 
Bcl-2 and Bcl-xL, pro-apoptotic proteins Bax, Bak and Bcl-xs , and pro-apoptotic 
“BH3-only” proteins Bid (BH3-interacting death agonist), Bad, Noxa, and Puma 
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(Haupt et al. 2003). Sequence comparisons of the Bcl-2 family members have 
revealed up to four conserved domains, called Bcl-2 Homology (BH) domains: 
BH1, BH2, BH3 and BH4 (Reed et al. 1998). Mutagenesis studies identified a 
conserved domain, BH3, within several of the pro-apoptotic Bcl-2 family 
members which was show to be critical for both dimerization with anti-apoptotic 
proteins such as Bcl-2 or Bcl-XL and for induction of apoptosis (reviewed in 
Kelekar and Thompson, 1998). Of note, several pro-apoptotic members of Bcl-2 
family protein contain the BH3 domain as their only apparent similarity with 
other members of the family, constituting the so-called “BH3-only” branch of 
the Bcl-2 family (Figure 1.10).  
 
 
   
         
 
 
 
Figure 1.10. The Bcl-2 family. The topologies of several of the Bcl-2 family proteins are 
depicted, illustrating the BH1, BH2,BH3 and BH4 domains, as well as the transmembrane (TM) 
domains. The Bcl-XL andBcl-Xs protein arise through alternative mRNA splicing mechanisms from 
the same gene. 
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Most Bcl-2 family members contain a C-terminal hydrophobic stretch of amino 
acids that anchors them in membranes, predominantly the outer mitochondrial 
membrane, endoplasmic reticulum and nuclear envelope. However, at least two 
pro-apoptotic Bh3-only proteins, Bad and Bid, lack membrane-anchoring 
domains (Wang et al. 1996; Yang et al. 1995). The locations of these proteins in 
cells is dynamically controlled by their association/dissociation with other Bcl-2 
family proteins, resulting in a regulated translocation between the cytosol and 
the surface of membranous organelles where other Bcl-2 family proteins reside. 
In the regulation of the intrinsic pathway, pro-apoptotic gene products such as 
Bax, Bid, Puma, Noxa, and p53AIP1 localize at the mitochondria and promote 
the loss of mitochondrial membrane potential and release of cytochrome c, 
resulting in the formation of the apoptosome complex with Apaf-1 and caspase 9 
(Nakano and Vousden, 2001; Yu et al. 2001; Oda et al. 2000; Matsuda et al. 
2002). These apoptosis-related gene products mentioned above are closely 
associated with p53 function. Bax was the first identified p53-regulated pro-
apoptotic Bcl-2 family member (Miyashita and Reed, 1995), and p53-responsive 
elements have been unequivocally identified in the Bax gene (Thornborrow et al. 
2002).  
Several Bcl-2 family proteins and mitochondrial proteins such as Puma, Noxa, 
p53AIP1, and PIGs are implicated in p53-dependent apoptosis. They are 
activated in a p53-dependent manner following DNA damage.  
Puma induces very rapid apoptosis, which occurs within hours following its 
expression (Nakano and Vousden, 2001; Yu et al. 2001; Oda et al. 2000). 
p53AIP1 can cause mitochondrial membrane potential dissipation by interacting 
with Bcl-2 (Matsuda et al. 2002). p53 also regulates the genes encoding Apaf-1, 
a key component of the apoptosome (Cecconi et al. 1998), and PIG3, which may 
cause mitochondrial depolarization (Flatt et al. 2000). Activation of death 
receptors can licence the mitochondrial apoptosis pathway by caspase-8 
mediated cleveage of Bid into tBid, connecting the extrinsic with the intrinsic 
apoptosis pathway in an amplification loop (Figure 1.11). 
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Figure 1.11. Cell death signalling regulated by the Bcl-2 family.  Prosurvival-members of the 
Bcl2 family preserve mitochondrial integrity by preventing activation of Bax and/or Bak until 
neutralised by BH3-only proteins. This leads to mitochondrial outer membrane permabilization, 
release of apoptogenic factors, including cytochrome c, required for apoptosome formation and 
activation of caspase cascade. Activation of death receptors can licence the mitochondrial 
apoptosis pathway by caspase-8 mediated cleavage of Bid into tBid, connecting the extrinsic with 
the intrinsic apoptosis pathway in an amplification loop. 
 
 
The quantitatively most important of these various mechanisms for controlling 
cell death most likely varies, depending on particular type of cell and the cell 
death stimulus involved. Moreover Bcl-2’s properties include transcriptional and 
post-transcriptional control of gene expression, protein turnover, alterations of 
protein conformations, protein phosphorylation, proteolytic processing, and 
protein translocation.  
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1.11 HMGA1 levels influence mitochondrial function 
Unique physical and biochemical properties give HMGA1 proteins the ability to 
function in the array of nuclear processes. These properties do not, however, 
exclude the possibility of a “non-nuclear” role for the proteins. Any region of 
DNA known to be high in AT content is thus a potential candidate for containing 
HMGA1 binding sites, regardless of specific sequence. This allows the proteins 
to directly interact with a number of platforms including satellite repeats (Strauss 
et al., Cell 1984), SARs/MARs (Zhao et al. 1993) and multiple gene promoter 
elements (Reeves et al. 2001). Functional versatility and mobility is increased by 
the relative small size (12-19 kDa) and inherent flexibility ( Lehn et al. 1988) of 
the HMGA1 proteins. As free molecules, the proteins have little if any 
secondary structure (Evans et al.1992; Evans et al. 1995).  
This characteristic is thought to play a significant role in the ability of HMGA1 
to interact with multiple proteins and DNA elements as well as to induce 
conformational changes in these substrates (Reeves et al. 2001). 
Multiple studies have shown that HMGA1 function is regulated by in vivo post-
translational phosphorylation, acetylation and methylation (Reeves et al. 2001; 
Banks et al. 2000; Edberg et al. 2004). These modifications results from both 
internal and external signaling events that affect important biological events 
such as cellular activation and proliferation, apoptosis and cell cycle 
progression. Moreover, secondary biochemical modifications contribute to the 
ability of the cell to control both the function and distribution of these highly 
mobile and dynamic proteins. In particular, the specific phosphorylation of two 
HMGA1 threonine residues by cdc2 kinase during the G2/M phase of  the cell 
cycle results in a 20-fold decrease in the DNA binding affinity of the modified 
protein, indicating the cell stage-specific mobilization of HMGA1 for an as yet 
undetermined function  
(Nissen et al. 1991). Initial synchronization studies revealed a dynamic, cell 
cycle-dependent translocation of HMGA1 proteins from the nucleus into the 
cytoplasm and mitochondria of NIH3T3 cells (Dement et al. 2005). HMGA1 
 31 
 
retains its DNA binding capabilities within the mitochondria and associates with 
the regulatory D-loop region in vivo.  
Another work reveals that HMGA proteins are located in the nuclei of normal 
cell except during the late S/G(2) phases of the cell cycle, when HMGA1 
proteins reversibly migrate to the mitochondria, where it binds to mitochondrial 
DNA (mtDNA). In many cancer cells, this controlled shuttling is lost and 
HMGA1 is found in mitochondria throughout the cell cycle (Mao L. et al., 
Mol.Cell.Biol.2009). These evidence indicate that this nucleocytoplasmic 
movement is very dynamic, is cell-cycle dependent and is both directional and 
reversible, with the protein moving from nucleus to the cytoplasm and then back 
again. The mitochondrial localization of the HMGA1 proteins opened new areas 
of research regarding possible organelle specific functions for the proteins 
respect to normal and abnormal cellular functions, including cancer.  
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2. AIMS OF STUDY 
 
The aim of the my study is to define the subcellular endogenous localization of 
HMGA1 proteins evaluating the presence of these proteins not only in the nuclei 
of cancer cell lines but also in the cytoplasm in order to identify the possible 
interactors in this cellular compartiment.  
In fact, even thought the HMGA1 proteins have been frequently detected in the 
cytoplasm of cancer cells, no deep investigation has been undertaken to clearly 
demonstrate the presence and the functions of these proteins in cytoplasm. 
On the basis of data that I have reported in the background, I focalized my 
attention on B-cell lymphoma gene 2 (Bcl-2) as possible cytoplasmic interactor.  
Bcl-2 is an anti-apoptotic protein anchored to external membrane of 
mitochondria that inhibits the release of cytocrome C into the cytosol wich, in 
turn, activates caspase -9 and caspase-3 leading to apoptosis.  
Moreover, Bcl-2 gene is altered in many tumours including melanoma, breast, 
prostate, and lung carcinomas, and its transcription is regulated by HMGA1.  
Therefore, my work aims to verify the localization of the HMGA1 protein at 
cytoplasmic level and its binding to Bcl-2 including the biological consequences 
of this interaction. 
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3. MATERIALS AND METHODS  
 
3.1 Cell culture and transfections  
HEK293, GC1, HeLa, HBL100, BT549, MDA-MB-231, MDA-MB-468, MCF7, 
T47D, ND7, and MEFs cells were maintained in DMEM with 10% fetal calf 
serum (GIBCO), glutamine, and antibiotics. H1299 cells were maintained in 
RPMI-1640 Medium with 10% fetal calf serum (GIBCO), glutamine, and 
antibiotics. Cells were transfected with plasmids by lipofectamine-plus reagent 
(Invitrogen) as suggested by the manufacturer. 
 
3.2 Expression constructs 
The pCMV/Hmga1b is described elsewhere (Pierantoni et al, 2001). 
pHaemagglutinin (pHA)-tagged Hmga1 expression plasmids containing the 
entire or various portions of the Hmga1 coding sequence were amplified and 
inserted into the pCEFL-HA expression vector: pHA-A2 (amino acids 1-109) is 
constituted by the entire coding sequence of the HMGA2; pHA-A1b (amino 
acids 1-96) is constituted by the entire coding sequence of the HMGA1b 
isoform; pHA-A1b (1-79) is constituted by the first 79 amino acids including the 
three AT-hook domains; pHA-A1b (1-63) is constituted by the first 63 amino 
acids including the first two AT-hook domains and the region between the 
second and the third AT-hook domains; pHA-A1b (1-53) is constituted by the 
first 53 amino acids including the first two AT-hook domains; pHA-A1b (1-43) 
is constituted by the first 43 amino acids including the first AT-hook domain and 
the region between the first and the second AT-hook domains; pHA-A1b (∆42-
52) contains the Hmga1b coding sequence deprived of the second AT-hook 
domain; pHA-A1b (23-96) contains the Hmga1b coding sequence deprived of 
the first 23 amino acids; pHA-A1b (31-96) contains the Hmga1b coding 
sequence deprived of the first 31 amino acids that include the first AT-hook 
domain. To construct the EGFP-Hmga1b expression vector, the entire Hmga1b 
coding sequence was amplified by PCR with pairs of primers linked to 
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restriction sites (EcoRI and KpnI) and cloned in the pEGFP-C2 plasmid 
(Clontech). 
 
3.3 Western blotting and immunoprecipitation assay 
TCE were prepared with lysis buffer (50mM Tris Hcl pH 7.5, 5mM EDTA, 
300mM NaCl, 150mM KCl, 1mM dithiothreitol, 1% Nonidet P40, and a mix of 
protease inhibitors). For co-immunoprecipitation experiments, antigens and Abs 
were incubated for 3 h and then supplemented with protein A-sepharose or G-
sepharose beads (Millipore). After 1 h, the beads were collected and washed five 
times with lysis buffer, and boiled in Laemmli sample buffer for immunoblotting 
analysis. Protein extracts and immunoprecipitated pellets were separated by 
SDS-PAGE, and then transferred onto Immobilon-P Transfer membranes 
(Millipore). Membranes were blocked with 5% non-fat milk proteins and 
incubated with Abs at the appropriate dilutions. The filters were incubated with 
horseradish peroxidase-conjugated secondary Abs, and the signals were detected 
with ECL (Amersham Pharmacia). The Abs used for immunoprecipitation and 
Western blotting purchased from Santa Cruz Biotechnology were: anti-HA 
(Y11), anti-Sp1 (H225), anti-p53 (DO1), anti-Bcl-2 (100), anti-Cytochrome c 
(7H8) and anti-γ-tubulin (C11); anti-COX IV (3E11), anti-Phospho-(ser15) p53 
(9284) and anti-Caspase-7 (9492) from Cell Signaling; anti-Caspase-9 
(MAB8301) purchased from R&D Systems; anti-HMGA1 are polyclonal Ab 
raised against a synthetic peptide located in the NH2-terminal region (Pierantoni 
et al, 2006). 
 
3.4 In vitro translation and protein-protein binding 
The pET2c-HMGA1b construct was previously described (Baldassarre et al, 
2003). His recombinant protein was produced in Escherichia coli BL21 cells. 
Stationary phase cultures of E. coli cells transformed with the plasmid of interest 
were diluted in LB with ampicillin (100 mg/ml), grown at 30°C to an OD600 of 
 35 
 
0.6 and induced with 0.1mM IPTG. After an additional 2 h at 30°C, the cultures 
were harvested and resuspended in 10 ml of cold PBS (140mM NaCl, 20mM 
sodium phosphate pH 7.4), 1mM phenylmethylsulfonyl fluoride (PMSF) and 
protease inhibitors (Boehringer). The cells were broken by French Press.  
The supernatant was purified by using nickel-agarose beads supplied with the 
His-Trap purification kit (Amersham Pharmacia) following the manufacturer’s 
instructions, eluted with 500mM imidazol and dialysed in PBS. The purified 
Bcl-2 and p53 proteins were respectively purchased from GenWay and BD 
Pharmingen. The recombinant proteins were subjected to protein-protein binding 
in vitro in NETN buffer (20mM Tris-HCl pH 8.0, 100mM NaCl, 1mM EDTA, 
and 0.5% Nonidet P-40) for 1 h at 4°C. Recombinant proteins and Abs were 
incubated for 3 h and then supplemented with protein A-sepharose or G-
sepharose beads (Millipore). The resins were then extensively washed in the 
same buffer. The bound proteins were separated by SDS-PAGE, and analyzed 
by Western blotting. 
 
3.5 Immunofluorescence 
Cells plated in 35-mm dishes were fixed in 2% formaldehyde in PBS and 
permeabilized in a solution of 0.25% Triton X-100 in PBS. Immunofluorescence 
was obtained with the anti-HA 12CA5 moAb (Roche) and the FITC-conjugated 
goat anti mouse IgG (Jackson). Cells were stained simultaneously for DNA with 
Hoechst 33342 before observation with a fluorescent microscope (Zeiss). For 
mitochondrial staining, cells transfected with EGFP-HMGA1b were stained with 
Mito-IDTM Red Detection Kit as suggested by the manufacturer.  
 
3.6 Viability, apoptosis and caspase detection 
Apoptosis was monitored by FACS, measuring the mitochondrial membrane 
potential (DF), determining the activation of Caspase-9 and TUNEL assay. Cells 
were harvested, pooled with the supernatant, washed once in PBS with 
Ca2+/Mg2+ and processed for the different assays. For FACS analysis, cells were 
trypsinized, fixed in 70% ethanol and stored at 4 °C for a few days. Then, cells 
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were washed with PBS w/o Ca2+ and Mg2+, stained with 50µg/ml propidium 
iodide containing RNase (20µg/ml) and analyzed with a FACS Calibur 
cytofluorimeter. For the measurement of the DF, the JC-1 (cationic dye that 
signal the loss of mitochondrial membrane) staining was used. After washing in 
PBS with Ca2+/Mg2+, cells were resuspended in complete medium and incubated 
with 2.5 mg/ml JC-1 (Molecular Probes) for 20 min at room temperature in the 
dark. After two washes in PBS with Ca/Mg, samples were placed on ice and 
immediately analyzed by a BD FACScan cytofluorimeter by using the BD 
CellQuest software package. For TUNEL assay, cells were fixed in 
paraformaldehyde solution (4% in PBS, pH 7.4) for 30 min at room temperature 
and permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on 
ice. Apoptotic nuclei were detected using TUNEL labelling reaction according 
to the manufacturer’s instructions (Roche Biochemicals). TUNEL labelling and 
phase contrast images were analyzed by AXIO VISION 3.0 program. Caspase-9 
colorimetric assay (PromoKine) was analyzed according to the manufacturer’s 
instructions. 
 
3.7 Isolation of nuclear/cytoplasmic fractions 
Nuclear and cytoplasmic fractions were prepared as follows: 1-2 x 106 cells, 
scraped off the plate with PBS, were resuspended in hypotonic lysis buffer 
(10mM HEPES pH 7.9, 10mM KCl, 0.1mM EDTA, 0.1mM EGTA) added with 
protease inhibitors (Roche). After resuspension, NP-40 was added to a final 
concentration of 0.6% and the nuclei were isolated by centrifugation at 10000 
r.p.m. for 30 s at 4°C. After removal of the supernatant (i.e. the cytoplasmic 
extract), nuclei were resuspended in nuclear extract buffer (20mM HEPES pH 
7.9, 25% glycerol, 0.4M NaCl, 0.1mM EDTA, 0.1mM EGTA), rocked for 15 
min at 4°C and then recovered by centrifugation at 14000 r.p.m. for 5 min at 
4°C. 
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3.8 Isolation of mitochondria and treatment with proteinase K in vitro 
Mitochondria were isolated by differential centrifugation, using Mitochondria 
Fractionation Kit (BioVision). For enzymatic digestion, isolated mitochondria 
were resuspended in suspension buffer and treated with proteinase K 0.2 mg/ml 
for 20 min at 30°C in the presence or absence of Triton X-100 (1% final 
concentration). PMSF was then added to a final concentration of 2mM to stop 
the reaction. 
3.9 Cytochrome C release from isolated and purified mitochondria 
Intact mitochondria were isolated as above described and incubated at 37°C for 
1 h with His-HMGA1b and recombinant p53 in MSB buffer (400mM mannitol, 
50mM Tris, pH 7.2, 10mM KH2PO4, 5 mg/ml BSA) containing a cocktail of 
protease inhibitors. Samples were centrifuged at 5500 r.p.m. for 15 min at 4°C. 
The resulting supernatant and pelleted mitochondrial fractions were analyzed by 
Western blot. Pelleted mitochondria were washed two times with MSB buffer 
before analysis.  
 
3.10 Immunohistochemistry 
For immunohistochemistry, 6µm paraffin sections were deparaffinised and then 
placed in a solution of absolute methanol and 0.3% hydrogen peroxide for 30 
min and then washed in PBS before immunoperoxidase staining. The slides were 
then incubated overnight at 4ºC in a humidified chamber with the antibodies 
diluted 1:100 in PBS. The slides were subsequently incubated with biotinylated 
goat anti-rabbit IgG for 20 min (Vectostain ABC kits, Vector Laboratories) and 
then with premixed reagent ABC (Vector) for 20 min. The immunostaining was 
performed by incubating the slides in diaminobenzidine (DAB-DAKO) solution 
containing 0.06 mM DAB and 2 mM hydrogen peroxide in 0.05% PBS, pH 7.6, 
for 5 min, and, after chromogen development, the slides were washed, 
dehydrated with alcohol and xylene and mounted with cover slips using a 
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permanent mounting medium (Permount). The antibodies used in this study were 
raised against the synthetic peptide SSSKQQPLASKQ specific for the HMGA 
protein. They were affinity purified against the synthetic peptide (Pierantoni et 
al, 2006). Tissue samples were scored as positive for immunohistochemistry 
when tissue immunoreactivity was detected in at least 10% of the cells. Negative 
controls were performed by omitting the first antibody. The specificity of the 
reaction was confirmed by the lack of tissue immunoreactivity after pre-
incubation of the antibody with molar excess of the HMGA1 synthetic peptide.  
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4. RESULTS 
 
4.1 HMGA1 is present at cytoplamic level other than in the    
      nucleus 
 
To determine whether HMGA1 proteins localize also at cytoplasmic level, we 
analyzed differential cell fractions from human embryonic kidney 293 cells 
(HEK293) transiently transfected with vectors encoding the full length 
haemagglutinin (HA)-tagged HMGA1b protein and a series of NH2- and 
COOH-terminal deletion mutants (Figure 4.1A). Western Blot analysis showed 
that the protein coded for the full-length HA-HMGA1b and almost all the HA-
HMGA1b deletion mutant constructs was present in both the nuclear and 
cytoplasmic extracts (Figure 1B). One exception was represented by the HA-
HMGA1b (1-43) construct that is deprivated of the second AT-hook domain that 
contains the nuclear signal localization (NSL): indeed, HMGA1b (1-43) showed 
only a cytoplasmic localization (Figure 4.1B). 
Sp1 and γ-tubulin were used as markers of nuclear/cytoplasmic separation as 
well as loading controls (Figure 4.1B); Sp1 is a nuclear protein and  the levels of 
γ-tubulin in cytoplasm are high. 
To confirm these data, we performed immunofluorescence studies, using HA 
antibodies and markers that selectively stain nucleus (Hoechst) in HEK293 cells 
transiently transfected with HA-HMGA1b deletion mutants constructs. 
The results, shown in Figure 4.1C, confirm that the HMGA1 full-length protein 
was detected in both the nuclear and cytoplasmic compartments after 
transfection with almost all the constructs, whereas the protein coded for the 
HA-HMGA1b (1-43) construct was located only in the cytoplasm.  
To better characterize the cellular localization of endogenous HMGA1 proteins, 
we analyzed total, nuclear, and cytoplasmic cell lysates from several normal and 
tumor-derived cell lines. Western Blotting analyses demonstrated that HMGA1 
localized at nuclear level only in normal cell lines, such as HEK293, neuronal 
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cell line (ND7), spermatogonia cell line (GC1) (Figure 4.1 D) and in two breast 
carcinoma cell lines (T47D and MCF7). Conversely, HMGA1 was present at 
cytoplasmic level other than in the nucleus in several breast (HBL100, BT549, 
MDA-MB-231, MDA-MB-468), lung (H1299), cervical (HeLa) cancer cell lines 
(Figure 4.1E).  
Interestingly, mouse embryonic fibroblasts (MEFs) behaved as most of the 
cancer cell lines showing HMGA1 expression in both the compartments (Figure 
4.1 E). Furthermore, HMGA1 was revealed at nuclear and cytoplasmic level also 
in human seminomas, whereas it was only nuclear in the normal testis (Figure 
4.1 E).The same experiments performed to analyze the cellular localization of 
the other member of the HMGA protein family, HMGA2, revealed that this 
protein was not detected at cytoplasmic level, but only in the nucleus (Figures 
4.1B and 4.1C).  
This result suggests that the cytoplasmic localization is restricted to only the 
HMGA1 members of the HMGA protein family and not for HMGA2 protein. 
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Figure 4.1 HMGA1b localize also in the cytoplasm. A) Diagram of the HA-tagged Hmga2 and 
Hmga1 wilde-type and deletion mutants used in western blotting and immunofluorescence 
analysis. The AT-hook domains (+) and the acidic tail (- - - - -) are indicated. B) Nuclear, 
cytoplasmic and total cell extracts from HEK293 cells were analyzed by Western blotting for the 
HA-HMGA2 and HA-HMGA1 wilde-type and mutant proteins. Sp1 and γ-tubulin were used as 
markers of nuclear/cytoplasmic separation as well as loading controls. C) Subcellular localization 
of HA-HMGA2 and HA-HMGA1 mutant proteins in HEK293 cells transfected with the indicated 
vectors. Nuclei were stained with Hoechst. 
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Figure 4.1. HMGA1 is located into the cytoplasm of cancer-derived cell lines and mouse 
embryonic fibroblasts. D) Total (T), nuclear (N) and cytoplasmic (C) cell extracts from HEK293, 
ND7, and GC1 cells were analyzed by Western blotting for the HMGA1 protein. E) Immunoblot 
analysis of HMGA1 expression in total (T), nuclear (N) and cytoplasmic (C) cell extracts from 
several breast tumor cell lines (HBL100, BT549, MDA-MB-231, MDA-MB-468, T47D, MCF7) 
(left), lung cancer cell line (H1299), cervical cancer cell line (HeLa), mouse embryonic fibroblasts 
(MEFs), human normal testis and seminomas (right). Sp1 and γ-tubulin were used as markers of 
nuclear/cytoplasmic separation as well as loading controls. 
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4.2  HMGA1 binds Bcl-2 in vitro and in vivo 
In order to characterize the role of HMGA1 proteins into the cytoplasm, we have 
thought to identify potential interactors of HMGA1 looked for new molecular 
partners. Since Bcl-2 localizes to mitochondrial outer and, to a lesser degree, 
inner membrane (Akao et al. 1994), and Bcl-2 has been recently identified by us 
as possible HMGA1-interacting partner by an Antibody Array TM (Hypromatrix 
Incorporation), we asked whether HMGA1 is able to bind Bcl-2.  
To this aim, we first evaluated the ability of HMGA1 and Bcl-2 purified proteins 
to interact in vitro. Indeed, Bcl-2 recombinant protein was incubated with the 
His-HMGA1b protein, that is the full length protein conjugated with tag of 
histidine, and the complexes were immunoprecipitated with anti-HMGA1 or 
anti-Bcl-2 antibodies and analyzed by Western blotting with the reciprocal 
antibodies.  
As shown in the Figure 4.2 A, HMGA1 and Bcl-2 proteins can directly interact.  
To verify this interaction in vivo, total cell extracts (TCE) from HEK293 cells 
transiently transfected with pCEFL-HA and pCEFL-HA/HMGA1b constructs 
were immunoprecipitated with anti-HA monoclonal antibodies and analyzed by 
Western blotting with anti-Bcl-2 polyclonal antibodies. Bcl-2 protein was 
present in the immunocomplexes from HA-HMGA1b transfected cells (Figure 
4.2 B, upper panel). The reciprocal experiment performed immunoprecipitating 
with anti-Bcl-2 antibodies and revealing with anti-HMGA1 antibodies 
confirmed this interaction (Figure 4.2 B, lower panel).  
Moreover, we have detected this association also between the endogenous 
proteins into cytoplasmic cell extract (CCE) from mammalian cancer cell lines 
MDA-MB-231 (Figure 4.2 C). 
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Figure 4.2. In vitro and in vivo characterization of the HMGA1/Bcl-2 interaction. A) The in 
vitro interaction between HMGA1b and Bcl-2 was assessed by immunoprecipitation assay with 
anti-HMGA1 (left panel) or anti-Bcl-2 (right panel) antibodies and blotting with the reciprocal 
antibodies after preincubation of the two proteins. The relative inputs are the His-HMGA1b and 
Bcl-2 recombinant proteins (loaded as controls). B) HEK293 cells were transfected with pCEFL-
HA and pCEFL-HA/Hmga1b vectors. After 48 h, total cell extracts were prepared, and equal 
amounts of proteins were immunoprecipitated with anti-HA (upper panel) or anti-Bcl-2 (lower 
panel) antibodies, and the immunocomplexes were analyzed by Western blotting using the 
reciprocal antibodies. Cellular extracts used for immunoprecipitation experiments were analyzed 
by Western blotting (right panels). C) Co-immunoprecipitation with the anti-HMGA1 or anti-Bcl-2 
antibodies with  the cytoplasmic endogenous HMGA1 and Bcl-2 proteins (CCE from parental 
MDA-MB-231 cells). IgG indicates the negative control of immunoprecipitation using unrelated 
antibodies. 
 
 
4.3 HMGA1 localizes in the internal compartments and on the 
outer membrane of mitochondria 
It has been previously published that members of the HMGA1 protein subfamily 
are localized, almost exclusively, in the nuclei of normal cells except during the 
late S and G2 phases of the cell cycle (Mao et al. 2009), when a minor protein 
fraction reversibly migrates out of the nucleus and into the mitochondria 
(Dement et al. 2005). However, this highly regulated shuttling is frequently 
disrupted in malignant cells that overexpress HMGA1 and these proteins are 
found in the mitochondria at all stages of the cell cycle (Dement et al., 2005, 
2007). To further characterize the role of HMGA1 into the cytoplasm and its 
association with mitochondria, we performed an immunofluorescence assay in 
HEK293 cells transfected with a vector encoding EGFP-HMGA1b protein, and 
incubated with a marker that selectively stains mitochondria, MitoTracker Red 
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dye. This red-fluorescent dye is able to stain mitochondria in live cells and its 
accumulation is dependent upon membrane potential. Merging of the signals by 
microscopy supported the partial co-localization of the cytoplasmic EGFP-
HMGA1b protein fraction at the mitochondria (Figure 4.3 A). Therefore, to 
determine the mitochondrial compartment in which HMGA1 localizes, we 
performed an enzymatic digestion of mitochondrial fractions from HMGA1b- 
and empty vector-transfected HEK293 (Figure 4.3 B) and MDA-MB-231 cells, 
that show the presence of HMGA1 at cytoplasmic level (Figure 4.3 C). After 
digestion with proteinase K, a non-specific protease unable to cross the outer 
mitochondrial membrane (Reef et al. 2006), HMGA1 was partially recoverable 
in the pellet, whereas Bcl-2, a tail-anchored protein to the mitochondrial 
membrane, was degraded. HMGA1 disappeared, as it occurs also for p53 that is 
able to binds HMGA1 and is present in cytoplasm, only after solubilisation of 
inner mitochondrial membranes by Triton X, a detergent capable to destroy 
internal and external mitochondrial membrane (Figure 4.3 B). These findings 
indicated that HMGA1 is located in the internal compartments and on the outer 
membrane of mitochondria (Figures 4.3 B and 4.3 C). As control of experiment, 
we used Cox-IV that is a protein located on the mitochondrial inner membrane. 
The degradation of CoxIV protein after treatment with Triton-X but not with 
proteinase K, confirmed the results. 
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Figure 4.4. HMGA1 localizes at the mitochondria in the internal compartments and on the 
outer membrane. A) EGFP-HMGA1b subcellular localization in HEK293 cells. Nuclei and 
mitochondria were respectively stained with Hoechst and MitoTracker Red dye. B) Mitochondrial 
fractions from control and HMGA1b-transfected HEK293 cells were enzymatically digested by 
Proteinase K in the presence or absence of Triton X-100 (1%) and subsequently analyzed by 
Western blotting for the indicated proteins. C) Mitochondrial fractions from MDA-MB-231 cells 
were treated as in B and analyzed by Western blotting for the indicated proteins. Cyclooxygenase 
IV (CoxIV), localized to the inner mitochondrial membrane, was used as loading control. 
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4.4 HMGA1 displaces Bcl-2 from the binding to p53 
We have previously demonstrated physical and functional interaction between 
HMGA1 and p53 (Pierantoni et al. 2006). This interaction modulates the 
transcription of p53 target genes such as Mdm2, p21waf1, Bax, Bcl-2, and inhibits 
p53-mediated apoptosis (Pierantoni et al. 2006, 2007; Esposito et al. 2010). 
As suggested by the data previously described, we asked whether HMGA1 
counteracts p53-mediated apoptosis acting also on the p53 interactors in the 
cytoplasm, in particular at mitochondrial level. It is known that the cytochrome 
C release mediated by p53 depends on its ability to bind members of the anti-
apoptotic Bcl-2 family (i.e. Bcl-2 and Bcl-xL) and to inactivate their inhibitory 
effect exerted on the pro-apoptotic proteins Bax and Bak (Mihara et al. 2003; 
Deng et al. 2006).  
Therefore, we investigated whether HMGA1 affects p53 binding to Bcl-2 by 
performing a co-immunoprecipitation assay in the MDA-MB-231 cells 
incubated with doxorubicin, that is able to activate the endogenous p53, in the 
presence or absence of HMGA1b protein overexpression.  
As expected, doxorubicin increases the formation of the Bcl-2/p53 complex 
leading to cell death, whereas HMGA1b overexpression significantly reduces 
the Bcl-2/p53 binding (Figure 4.4 A).To confirm this result, we used a cell-free 
system in which p53 and Bcl-2 recombinant proteins were incubated in presence 
or not of a recombinant wild-type HMGA1b protein. As shown in Figure 4.4 B, 
HMGA1b recombinant protein displaced Bcl-2 from the binding to p53.  
This result demonstrates that HMGA1b directly interferes with the p53/Bcl-2 
binding. 
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Figure 4.4. HMGA1 displaces Bcl-2 from the binding to p53. A) Lysates from MDA-MB-231 
cells transfected with control or HMGA1b expressing vectors treated or not with doxorubicin were 
subjected to immunoprecipitation with anti-Bcl-2 antibodies,  then immunocomplexes were 
analyzed by Western blotting using p53 antibodies. Western blot with Bcl-2 antibodies was used 
as a control of the equal loading of the immunoprecipitated Bcl-2 protein (left panel). Cellular 
extracts used for immunoprecipitation experiments were analyzed by Western blot with specific 
antibodies to verify protein expression levels (right panel). ϒ-Tubulin expression was used as a 
control for equal protein loading. B) p53 and Bcl-2 recombinant proteins were co-
immunoprecipitated in the presence or absence of His-HMGA1b recombinant protein. The 
samples were separated by SDS-PAGE and transferred on  Immobilon-P membranes. The filters 
were probed with either p53 or Bcl-2 antibodies (left panel). Western blotting analysis showed the 
amount of recombinant proteins used (right panel). 
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4.5 HMGA1 counteracts p53-intrinsic apoptosis 
The data shown above strongly suggest that the presence of HMGA1 at 
mitochondria may affect p53-mediated mitochondrial apoptosis (also called p53-
intrinsic apoptosis) through the reduction of p53/Bcl-2 binding. Indeed, p53 
activates the apoptosis through two distinct pathways: transcriptional activation 
of proapoptotic genes and facilitation of mitochondrial outer membrane 
permeabilization (MOMP) with release of cytochrome C (Chipuk & Green, 
2006). Earlier studies on p53-intrinsic apoptosis have pointed to p53 ability to 
permeabilize membranes of isolated mitochondria and permit cytochrome C 
release (Mihara et al, 2003; Chipuk et al, 2004; Deng et al, 2006).  
Therefore, we investigated whether HMGA1 counteracts p53-mediated MOMP 
in this cell-free system by testing the ability of recombinant p53 to permeabilize 
mitochondria isolated from HEK293 or MCF7 in presence or absence of 
HMGA1b recombinant protein. As expected, p53 caused release of cytochrome 
C from HEK293 and MCF7 mitochondria (Figure 4.5 A), whereas the presence 
of HMGA1 greatly reduced such release resulting in depletion of cytochrome C 
from the supernatant fraction.  
These data strongly support the existence of a negative role of mitochondrial-
localized HMGA1 on the p53 permeabilization function. To verify whether the 
mitochondrial HMGA1 activity has functional effects, HEK293 and MCF7 cells 
were transfected with control or HMGA1b expressing vectors and treated with a 
lethal dose of UV (40 J/m2) to induce cytochrome C release mediated by p53 
activity. As expected, UV treatment induces cytochrome C release into the 
cytosolic fraction of control cells at the indicated time (Figures 4.5B and 6C).  
No such effect could be observed in HEK293 and MCF7 cells transfected with 
HMGA1b expression vector (Figures 4.5 B and 6C).  
The inhibitory effect of HMGA1 on p53-induced cytochrome C release was 
further confirmed analyzing mitochondrial and cytosolic fractions isolated from 
wild-type and null MEFs for the hmga1 gene after UV irradiation.  
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Figure 4.5 D shows that UV light was less efficient in triggering the release of 
cytochrome C from the mitochondria of wild-type MEFs compared with 
mitochondria from hmga1 minus MEFs. Consistently, HEK293 cells 
overexpressing HMGA1b protein showed a reduction of caspase 9 cleavage and 
a decreased number of apoptotic cells after UV irradiation in comparison with 
the control cells (Figure 4.6 E, left panel and right panel, respectively).  
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Figure 6. HMGA1 counteracts p53-mediated release of cytochrome C. A) Mitochondria 
isolated from HEK293 and MCF7 cells transfected with HMGA1 or the backbone vectors were 
incubated with p53 recombinant protein. After 60 min incubation at 37°C, reactions were 
centrifuged, and pellet and supernatant fractions analyzed by Western blot. B-C) HEK293 and 
MCF7 cells were transfected with HMGA1 expressing vector and, after 24 h, cells were treated or 
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not with 40 J/m2 of UV irradiation. At the indicated time points, mitochondrial and cytosolic 
fractions were collected and analyzed by Western blotting with the indicated antibodies. D) Wild-
type and hmga1 null MEFs were either untreated or treated with 40 J/m2 of UV irradiation. At the 
indicated time points, mitochondrial and cytosolic fractions were collected and analyzed by 
Western blotting. Cytosolic and mitochondrial contamination was verified by CoxIV and γ-Tubulin 
used also as loading control. E) HEK293 cells were treated as in B, and apoptosis was assessed 
by Western blotting analysis of Caspase-9 cleavage (left panel) and counting the number of 
apoptotic cells by FACS (right panel). 
 
 
 
4.6 HMGA1 inhibits p53-mediated apoptosis by a           
transcriptional-independent mechanism  
It has been already demonstrated that HMGA1 binds to p53 and inhibits its 
transcriptional activity. Therefore, to exclude that HMGA1 might regulate 
mitochondrial function and inhibit apoptosis through mechanisms independent 
from its mitochondrial localization but just altering p53 transcriptional activity, 
HEK293 cells were treated with α-amanitin, a specific inhibitor of RNA 
polymerase II-dependent transcription and an activator of p53-mitochondrial 
apoptosis (Arima et al., 2005). In the presence of α-amanitin, overexpression of 
HMGA1 was still able to reduce the number of HEK293 cells with depolarized 
mitochondria (Figure 4.6 A). To depolarized HEK293 cells, we have used a JC-1 
Assay Kit using JC1, a cationic dye that signal the loss of mitochondrial 
membrane. As expected, HMGA1 was also able to reduce the percentage of 
apoptotic cells (Figure 4.6 B) and caspase 9 activation (Figure 4.6 C) following 
treatment with α-amanitin in comparison with the control cells.  
The same results were obtained in MCF7 cells, where HMGA1 overexpression 
counteracts caspase 7 and caspase 9 cleavages after α-amanitin treatment (Figure 
4.6 D). Furthermore, the HA-HMGA1b (1-43) deletion mutant protein, which 
localizes only into the cytoplasm, was still able to inhibit caspase 9 activation 
following UV exposure. Indeed, it only partially counteracts cell apoptosis in 
comparison with the HA-HMGA1b full length protein (Figure 4.6 E).  
Therefore, these results confirm the transcription-independent activity of 
HMGA1 in the repression of apoptosis and further support its negative 
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regulation towards p53-intrinsic apoptosis leading to the conclusion that 
HMGA1 can inhibit apoptosis through transcriptional and non-transcriptional 
pathways.  
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Figure 4.6. Transcription-independent activity of HMGA1 on inhibition of apoptosis. A-C) 
HEK293 cells were transfected with HMGA1 or the backbone vectors and after 24 h either 
untreated or treated with 10 µg/ml α-amanitin. After 16 h, cell death was assessed by JC-1 assay 
(A), by counting the number of apoptotic cells by FACS (B), by Caspase-9 colorimetric assay and 
Western blotting analysis of Caspase-9 cleavage (C). The data are representative of three 
independent experiments. Each bar represents the mean and lines indicate standard deviation 
(s.d.) (t-test, *P<0.05). D) MCF7 cells were treated as in A and apoptosis was assessed by 
Western blotting analysis of Caspase-7 and Caspase-9 cleavage. E) HEK293 cells were 
transfected with control, HA-HMGA1b or HA-HMGA1b (1-43) expressing vectors and after 24 h 
either untreated or treated with 30 J/m2 of UV irradiation. After 16 h, cell death was assessed by 
Caspase-9 colorimetric assay (upper panel) and Tunel assay (lower panel). Each bar represents 
the mean of three independent experiments, and lines indicate standard deviation (s.d.) (t-test, 
*P<0.05, **P<0.05). 
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4.7 Cytoplasmatic localization of HMGA1 correlates with higher 
aggressive tumor histotype 
The interaction of HMGA1 protein with Bcl-2 and a consequent possible 
impairment of the p53 apoptotic activity would suggest another oncogenic effect 
of HMGA1, other those due to its regulation of the transcriptional activity, and 
thereby an higher aggressivity of the cells where HMGA1 is located at the 
cytoplasmic level.  
Then, we proceeded to the analysis of thyroid, breast and colon carcinoma 
samples at different degree of malignancy to correlate the HMGA1 cytoplasmic 
location with the tumour malignancy. 
Therefore, we analyzed the expression and localization of the HMGA1 protein 
in differentiated and undifferentiated thyroid carcinomas by 
immunohistochemistry. As shown in Figure 4.7, representative papillary and 
follicular thyroid carcinomas, that are well-differentiated and poorly aggressive 
carcinomas, showed a specific nuclear staining for HMGA1 (Figures 4.7 A and 
B, respectively). Conversely, anaplastic thyroid carcinomas, that represent one 
of the most aggressive tumor in the mankind, evidenced a strong cytoplasmic 
staining (a representative case is shown in Figure 4.7 C). Equally, a strong 
HMGA1 cytoplasmic staining was also found in aggressive breast and colon 
carcinomas (representative cases are shown in Figures 4.7 E and 4.7 G, 
respectively), whereas In Situ breast ductal carcinomas and colon adenomas 
showed nuclear specific staining for HMGA1 (representative cases are shown in 
Figures 4.7 D and 4.7 F, respectively).  
These data have confirmed by the analysis of data reported in Table 4.7. 
Analyzing some number of tumoral samples by immunohistochemistry, we have 
noted that the percentage of samples that present a cytoplasmic localization of 
HMGA1 are undifferentiated tumours or carcinomas. 
 Taken together, these data indicate a correlation between HMGA1 positivity at 
cytoplasmic level and a higher aggressive tumour histotype.  
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Figure 4.7. Immunohistochemical analysis of HMGA1 protein expression in human tumors. 
Paraffin sections were analyzed by immunohistochemistry using home made anti-HMGA1 rabbit 
polyclonal antibodies. A) Immunostaining of a papillary thyroid carcinoma (200 x). Specific 
nuclear immunoreactivity was observed. B) Immunostaining of  a follicular thyroid carcinoma (200 
x). Specific nuclear immunoreactivity was observed in follicular cells. C) Immunostaining of a 
anaplastic thyroid carcinoma (200 x). A strong cytoplasmic staining was observed in 
undifferentiated cancer cells. D) Immunostaining of an In Situ breast ductal carcinoma showing 
nuclear immunoreactivity and a very weak cytoplasmic staining (200 x). E) Immunostaining of an 
aggressive ductal breast carcinoma (G3) showing a strong cytoplasmic staining (200 x). F) 
Immunostaining of a colon adenoma with severe dysplasia showing nuclear immunoreactivity. G) 
Immunostaining of a colon carcinoma showing a strong cytoplasmic staining in the malignant 
cells. 
 
Table 4.7 
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5. DISCUSSION AND CONCLUSIONS 
 
The High mobility Group A proteins (HMGAs) are a family of small non-
histone chromatin factors that do not have transcriptional activity per se but act 
like architectural factors (Muller et al. 2001). 
They are able to bind directly the DNA, modifying its conformation and 
facilitating the binding of a group of transcriptional factors. They can also 
influence gene transcription through direct protein-protein interactions with 
transcription factors leading nuclear multiprotein complexes formation and 
promoters and enhancers of several genes (Reeves et al. 2001), (Fusco and 
Fedele 2007) . 
HMGA proteins overexpression is a feature of several human malignancies and 
it is clearly demonstrated that they play a critical role in this process since the 
block of their expression inhibits cell transformation. They represent a good 
prognostic marker of neoplasia. These proteins have been identified as nuclear 
proteins; they exert their oncogenic activity acting at transcriptional level. 
Indeed, it has been reported that they are able to:  
a) induce the activity of the transcription factor E2F1 and AP1 ; 
b) induce Cyclin A expression; 
c) inactivate p53-induced apoptosis; 
d) impair DNA repair; 
e) enhance the expression of proteins involved in inflammation; 
f) modulate the expression of microRNAs and gene involved in epithelial-
mesenchymal transition. 
In this study, I demonstrated that HMGA1 localizes not only in the nuclei but 
also at cytoplasmic level where interacts with Bcl-2 at mitochondria and inhibits 
the p53-intrinsic-apoptotic pathway. I have reported that HMGA1 is located also 
in the cytoplasm of cancer cell lines and mouse embryonic fibroblasts.  
This localization is restricted only for HMGA1 family members and not for 
HMGA2, that is exclusively in the nucleus. In the cytoplasm HMGA1 has a 
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diffuse localization at mitochondria in which it is present in the internal 
compartments as well as on the outer membrane.  
HMGA1 is able to bind Bcl-2 that is anchored to the external mitochondrial 
membrane interfering with the binding between Bcl-2 and p53, thus 
counteracting the cytochrome C release. This results evident after lethal dose of 
UV light because the levels of cytochrome C in cytosol decreased in presence of 
HMGA1 overexpressed. Previously, our group demonstrated that HMGA1 
sustains Bcl-2 transcription and at the same time promotes Bcl-2 activity also at 
cytoplasmic level. Then, to exclude the transcriptional activity of HMGA1 
proteins in inhibiting the mitochondria p53-mediated apoptosis, I have 
performed experiments using α-amanitin. These experiments have demonstrated 
that HMGA1 is able to inhibit the intrinsic p53-mediated apoptosis by 
transcriptional independent mechanisms. The interaction of HMGA1 protein 
with Bcl-2 and the possible impairment of the p53 apoptotic activity would 
suggest another oncogenic effect of HMGA1 other those due to its regulation at 
the transcriptional level, and thereby a higher aggressivity of the cells where 
HMGA1 is located at the cytoplasmic level . Therefore, HMGA1 overexpression 
contributes to cancer progression impairing p53 activity, notwithstanding the 
absence of p53 gene mutations and/or deletions, through the already studied 
transcriptional activity (Pierantoni et al, 2006, 2007; Esposito et al, 2010) and, in 
addition, through this new cytoplasmic mechanism.  
Consistently, the HMGA1 cytoplasmic localization correlates with a more 
aggressive histotype of cancer. Indeed, HMGA1 is localized in the cytoplasm of 
anaplastic thyroid carcinomas, colon and breast carcinomas, whereas it is located 
only at nuclear level in the differentiated thyroid carcinomas, in situ breast 
carcinomas and in colon adenomas.  
Therefore, the data reported here demonstrate the ability of the HMGA1 proteins 
to localize in the cytoplasm, in particular at mitochondria, where they inhibit 
apoptosis by displacing p53 from Bcl-2, thus sustaining the Bcl-2 oncogenic 
activity.  
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